GU Cancers 2024 | Investigating novel treatment options for BCG-unresponsive urothelial carcinoma

Joseph Jacob, MD, MSc, Upstate Medical University, Syracuse, NY, gives an overview of clinical trials assessing novel therapies for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), such as the ABLE-41 study (NCT06026332), CORE-001 (NCT04387461), and SunRISe-1 (NCT04640623) trials. In the case of the latter trial, most patients would refuse a radical cystectomy, when questioned on the topic, highlighting the demand for these therapies. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.